Search clinical trials for: etoposide, cytarabine, mercaptopurine

Total 2403 results

Beijing Tongren Hospital

Recruiting

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma

China
University of Birmingham
University of Oslo; The Leeds Teaching Hospitals NHS Trust; University of Padova and other collaborators

Active, not recruiting

Paediatric Hepatic International Tumour Trial (PHITT)

Carcinoma, Hepatocellular | Hepatoblastoma

United Kingdom, France, Austria, Israel, Spain, Belgium, Czechia, Finland, Germany, Ireland, Netherlands, Norway, Poland, Switzerland
University of Miami

Completed

Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment (smoker3)

Smoking

United States
University of Cologne

Completed

HD11 for Intermediate Stages

Hodgkin´s Lymphoma
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

B Acute Lymphoblastic Leukemia | Central Nervous System Leukemia | Testicular Leukemia | B Lymphoblastic Lymphoma | Mixed Phenotype Acute Leukemia

United States, Canada, Australia, Puerto Rico, New Zealand
M.D. Anderson Cancer Center
Novartis

Completed

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

Leukemia | Acute Lymphocytic Leukemia

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Sarcoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Takeda; Amgen

Recruiting

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | t(9;22) | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | BCR-ABL1...

United States
Fondazione Italiana Linfomi ONLUS

Completed

Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

Aggressive Non-Hodgkin Lymphoma

Italy
NewLink Genetics Corporation

Completed

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Glioma | Glioblastoma Multiforme | Gliosarcoma | Ependymoma | Medulloblastoma | Diffuse Intrinsic Pontine Glioma | Malignant Brain Tumor | Primary CNS Tumor

United States
Zhejiang Cancer Hospital

Unknown

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

China
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Lymphocyte-Rich Classical Hodgkin Lymphoma | Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma | Recurrent Mixed Cellularity Classical Hodgkin Lymphoma | Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma | Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma | Refractory Mixed... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Gonorrhea Male

United States
University of Birmingham
Assistance Publique - Hôpitaux de Paris; Pfizer; Cancer Research UK; National Cancer...

Recruiting

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

Acute Myeloid Leukaemia

France, Switzerland, United Kingdom, New Zealand, Australia, Ireland
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Neuroblastoma | Solid Tumors | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL)

France, United States, Spain, Canada, United Kingdom, Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Janssen Research & Development, LLC

Not yet recruiting

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Acute Leukemias

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The First Affiliated Hospital of Nanchang University; Guangzhou First People... and other collaborators

Recruiting

Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children (SCCLG-M5)

Leukemia, Monocytic, Acute | Pediatric AML

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma | Liver Lymphoma

United States
Fujian Medical University

Active, not recruiting

R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL

Diffuse Large B-cell Lymphoma

China
European Organisation for Research and Treatment...

Active, not recruiting

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study (COBRA)

Advanced Hodgkin Lymphoma

Belgium, Spain, Netherlands, Denmark, Poland, Portugal, Slovakia
Peking University
Peking University International Hospital; Jiangxi Provincial Cancer Hospital; Shandong Tumor Hospital

Unknown

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Experimental Tumor

China
UNC Lineberger Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

Follicular Lymphoma | Burkitt Lymphoma | Diffuse Large B-cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Lymphoma

United States
Washington University School of Medicine
Karyopharm Therapeutics Inc

Completed

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
International Extranodal Lymphoma Study Group (IELSG)

Completed

Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Central Nervous System Lymphoma

Germany, Italy, United Kingdom, Switzerland
M.D. Anderson Cancer Center

Completed

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
University of California, San Francisco
Incyte Corporation

Not yet recruiting

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Hemophagocytic Lymphohistiocytoses

United States
Peking Union Medical College Hospital
Peking University First Hospital; Chinese PLA General Hospital; Peking University... and other collaborators

Recruiting

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

T Cell Non-Hodgkin's Lymphoma

China
The Hospital for Sick Children
Terry Fox Foundation

Active, not recruiting

Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma

Retinoblastoma

Canada, Chile, India, Singapore
Baylor College of Medicine

Completed

High-Risk Neuroblastoma Chemotherapy Without G-CSF (SPRING)

Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Lymphoma | Cardiac Toxicity

United States, Canada, Switzerland
Tanja Andrea Gruber
Amgen; Kura Oncology, Inc.; Pediatric Oncology Experimental Therapeutics Investigators... and other collaborators

Recruiting

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Lymphoblastic Leukemia

United States
University of Washington
National Cancer Institute (NCI)

Recruiting

Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Children's Oncology Group

Recruiting

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Bilateral Retinoblastoma | Childhood Intraocular Retinoblastoma | Unilateral Retinoblastoma | Group D Retinoblastoma | Stage I Retinoblastoma

United States, Australia
Weill Medical College of Cornell University
FDA Office of Orphan Products Development; The Leukemia and Lymphoma Society; Karyopharm Therapeutics Inc

Completed

KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma (KPT-330+RICE)

Diffuse Large B-Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

Breast Cancer

United States
St. Jude Children's Research Hospital
Assisi Foundation

Completed

Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies

Non-Hodgkin's Lymphoma | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia

United States
University Hospital Freiburg
University Hospital Tuebingen

Unknown

Freiburg ZNS-NHL Study

Primary Non Hodgkin Lymphoma of the Central Nervous System

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Cutaneous Melanoma | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm | Recurrent Lip and Oral Cavity Carcinoma | Recurrent Malignant Endocrine... and other conditions

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Lymphoma

United States, Canada, South Africa
National Cancer Institute (NCI)

Completed

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage

Extensive Stage Small Cell Lung Carcinoma | Recurrent Small Cell Lung Carcinoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma

Sarcoma

United States, Canada, Australia, Switzerland, Puerto Rico
University of Iowa
National Cancer Institute (NCI)

Terminated

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

Multiple Myeloma

United States
University of Arkansas
National Institutes of Health (NIH); Ortho Biotech Clinical Affairs, L.L.C.

Completed

Effects of Exercise in Combination With Epoetin Alfa

Multiple Myeloma

United States
Children's Cancer and Leukaemia Group

Unknown

Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis

Nonneoplastic Condition

United Kingdom

Search clinical trials for: etoposide, cytarabine, mercaptopurine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations